Onyx Biotec last traded at ₹38.00 (2026-10-13). Over the past month the stock moved -1.9%, three months the stock moved -2.6%, year the stock moved -8.8%. Its closing range over 52 weeks is ₹29.80 – ₹44.25, with the latest close 14.1% below the high.
Closing prices up to 2026-10-13.
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]
Business Overview:[1] OBL is associated with the healthcare segment and is a supplier of sterile pharmaceutical products to major corporations. Presently, OBL manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. It provides end-to-end product development and manufacturing solutions and its services also include preparation and filing of regulatory dossiers in the Indian and global markets.
In the latest quarter (Mar 2026), Onyx Biotec reported sales of ₹34.88 crore (+16.8%) and net profit of ₹0.69 crore (-66.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 34.88 | 2.45 | 7.02 | 0.69 | 0.38 |
| Sep 2025 | 34.59 | 0.94 | 2.72 | -0.90 | -0.50 |
| Mar 2025 | 31.80 | 4.63 | 14.56 | 1.97 | 1.09 |
| Sep 2024 | 30.15 | 5.71 | 18.94 | 2.99 | 2.24 |
| Mar 2024 | 29.86 | 4.91 | 16.44 | 2.03 | 1.52 |
| Sep 2023 | 23.89 | 3.42 | 14.32 | 1.60 | 2.71 |
| Sep 2025 | Mar 2026 | |
|---|---|---|
| Sales growth | +44.8% | +16.8% |
| Operating profit growth | -72.5% | -50.1% |
| Net profit growth | -156.3% | -66.0% |
| EPS growth | -118.5% | -75.0% |
| OPM % | 2.7% | 7.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Onyx Biotec reported sales of ₹69.47 crore (+12.1%) and net profit of ₹-0.21 crore (-104.2%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 69.47 | 3.40 | 4.89 | -0.21 | -0.12 |
| Mar 2025 | 61.95 | 10.35 | 16.71 | 4.95 | 2.73 |
| Mar 2024 | 53.75 | 8.33 | 15.50 | 3.03 | 2.27 |
| Mar 2023 | 39.49 | 4.50 | 11.40 | 1.84 | 3.12 |
| Mar 2022 | 44.86 | 5.77 | 12.86 | 3.35 | 5.68 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales growth | -12.0% | +36.1% | +15.3% | +12.1% |
| Operating profit growth | -22.0% | +85.1% | +24.2% | -67.1% |
| Net profit growth | -45.1% | +64.7% | +63.4% | -104.2% |
| EPS growth | -45.1% | -27.2% | +20.3% | -104.4% |
| OPM % | 11.4% | 15.5% | 16.7% | 4.9% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Onyx Biotec.
Get Free AI Stock Analysis FREE →No recent news available for Onyx Biotec.
Onyx Biotec shares were last quoted at ₹38.00 (+0.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Onyx Biotec has a price-to-earnings (P/E) ratio of -315.00 and a price-to-book (P/B) ratio of 1.24. The industry P/E is 52.82.
The 52-week high of Onyx Biotec is ₹49.65 and the 52-week low is ₹24.20.
The market capitalisation of Onyx Biotec is about ₹68.54 crore.
In the latest quarter (Mar 2026), Onyx Biotec reported sales of ₹34.88 crore (+16.8%) and net profit of ₹0.69 crore (-66.0%), compared with the same quarter last year.
Promoters hold about 65.10% of Onyx Biotec.
Onyx Biotec belongs to the Pharmaceuticals & Drugs sector.